Terbufibrol has been shown highly active in reducing serum total cholesterol (TC) levels in the normal and hypercholesterolemic male rat.
Terbufibrol (20-200 mg/kg) is active in lowering serum TC in animals on all 3 diets, but the extent of cholesterol reduction varies in the order cholesterol (HC)>high protein and fat diet (HPF)>N (max. reductions: 154, 80, and 70%, respectively). Clofibrate (200 mg/kg) decreases TC by a maximum of 28% with the HPF-diet and 13% with the N-diet but is inactive with the HC-diet. Cholestyramine (400 mg/kg/day) is inactive in HPF-fed animals but reduces TC in HC-fed animals by 45%. With the HPF-diet nicotinic acid (200 mg/kg) is inactive. Terbufibrol lowers HDL, HDL-TC, LDL, LDL-TC and LDL-TC/PL in animals fed HPF-diet. A greater decrease of LDL-TC occurres with increasing dose. The main effect of Clofibrate (200 mg/kg) is to reduce HDL and HDL-TC and to increase LDL[1].
[1]. Howard AN, et al. The hypocholesterolemic effect of terbufibrol and other drugs in normal and hypercholesterolemic baboons. Atherosclerosis. 1979 Apr;32(4):367-80.